Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01747798 · ClinicalTrials.gov registry record · Early Phase 1
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01747798: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01747798 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01747798, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin, may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG auranofin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2015-04-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01747798
The ClinicalTrials.gov registry entry for NCT01747798 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01747798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01747798 about?
NCT01747798 is a clinical study titled "Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin, may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT01747798?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2012-11-02. Estimated completion is 2015-04-06.
What interventions are being tested in trial NCT01747798?
The interventions under investigation include: laboratory biomarker analysis (OTHER), auranofin (DRUG).
Who is sponsoring clinical trial NCT01747798?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.